Compulsory licensing of patented pharmaceutical inventions: evaluating the options
Identifieur interne : 000054 ( Ncbi/Curation ); précédent : 000053; suivant : 000055Compulsory licensing of patented pharmaceutical inventions: evaluating the options
Auteurs : Jerome H. ReichmanSource :
- The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics [ 1073-1105 ] ; 2009.
Abstract
In this Comment, the author traces the relevant legislative history pertaining to compulsory licensing of patented pharmaceuticals from the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement of 1994 to the 2003 waiver to, and later proposed amendment of, article 31, which enables poor countries to obtain needed medicines from other countries that possess manufacturing capacity. The Comment then evaluates recent, controversial uses of the relevant legislative machinery as viewed from different critical perspectives. The Comment shows how developing countries seeking access to essential medicines can collaborate in ways that would avoid undermining incentives to innovation and other social costs attributed to compulsory licensing. It ends by defending the legality of recent measures taken to promote public health in developing countries, and by reminding developed countries that unilateral retaliation against such measures is demonstratably illegal under WTO foundational law and jurisprudence.
Url:
DOI: 10.1111/j.1748-720X.2009.00369.x
PubMed: 19493070
PubMed Central: 2893582
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000282
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000282
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000410
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000054
Links to Exploration step
PMC:2893582Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Compulsory licensing of patented pharmaceutical inventions: evaluating the options</title><author><name sortKey="Reichman, Jerome H" sort="Reichman, Jerome H" uniqKey="Reichman J" first="Jerome H." last="Reichman">Jerome H. Reichman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">19493070</idno><idno type="pmc">2893582</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893582</idno><idno type="RBID">PMC:2893582</idno><idno type="doi">10.1111/j.1748-720X.2009.00369.x</idno><date when="2009">2009</date><idno type="wicri:Area/Pmc/Corpus">000282</idno><idno type="wicri:Area/Pmc/Curation">000282</idno><idno type="wicri:Area/Pmc/Checkpoint">000410</idno><idno type="wicri:Area/Ncbi/Merge">000054</idno><idno type="wicri:Area/Ncbi/Curation">000054</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Compulsory licensing of patented pharmaceutical inventions: evaluating the options</title><author><name sortKey="Reichman, Jerome H" sort="Reichman, Jerome H" uniqKey="Reichman J" first="Jerome H." last="Reichman">Jerome H. Reichman</name></author></analytic><series><title level="j">The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics</title><idno type="ISSN">1073-1105</idno><idno type="eISSN">1748-720X</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">In this Comment, the author traces the relevant legislative history pertaining to compulsory licensing of patented pharmaceuticals from the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement of 1994 to the 2003 waiver to, and later proposed amendment of, article 31, which enables poor countries to obtain needed medicines from other countries that possess manufacturing capacity. The Comment then evaluates recent, controversial uses of the relevant legislative machinery as viewed from different critical perspectives. The Comment shows how developing countries seeking access to essential medicines can collaborate in ways that would avoid undermining incentives to innovation and other social costs attributed to compulsory licensing. It ends by defending the legality of recent measures taken to promote public health in developing countries, and by reminding developed countries that unilateral retaliation against such measures is demonstratably illegal under WTO foundational law and jurisprudence.</p></div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000054 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000054 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= PMC:2893582
|texte= Compulsory licensing of patented pharmaceutical inventions: evaluating the options
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:19493070" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a OpenAccessBelV2
| This area was generated with Dilib version V0.6.25. |  |